Please login to the form below

Not currently logged in
Email:
Password:

Coherus

This page shows the latest Coherus news and features for those working in and with pharma, biotech and healthcare.

Amgen biosimilar matches AbbVie's Humira in psoriasis trial

Amgen biosimilar matches AbbVie's Humira in psoriasis trial

Other companies such as Boehringer Ingelheim, Novartis unit Sandoz and Coherus are also developing biosimilars of Humira.

Latest news

  • Baxter names biopharma spin-off Baxalta Baxter names biopharma spin-off Baxalta

    The company also has ambitions to enter the biosimilars category on the back of the acquisitions of Coherus Biosciences and Momenta, and says these and other new products in the pipeline

  • Baxter taps Coherus for Enbrel biosimilar Baxter taps Coherus for Enbrel biosimilar

    Baxter has forged a $246m alliance with Coherus Biosciences to develop a biosimilar version of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel. ... The latest collaboration with Coherus "allows us to partner with a company that brings

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    255. Coherus Biosciences / Baxter International. Licence. Etanercept biosimilar for rhematoid arthritis.

  • Pharma deals during September 2013 Pharma deals during September 2013

    Continuing in the RA space is Baxter's exclusive collaboration with Coherus Biosciences, a biosimilar company, to develop and commercialise a biosimilar to etanercept (Enbrel).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Michael Fleming joins biosimilars firm Coherus Michael Fleming joins biosimilars firm Coherus

    He has experience at Elan, Genentech and GSK. Coherus Biosciences has named Michael Fleming as senior VP, commercial strategy. ... Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics